Multiple Sclerosis Webinar: Ocrelizumab Q&A with Dr. Tim Vollmer
The FDA officially approved Ocrelizumab (brand name: Ocrevus) for use in multiple sclerosis treatment on March 28, 2017. In this live Q&A, Dr. Tim Vollmer answers some common questions on this new option for MS patients.
Видео Multiple Sclerosis Webinar: Ocrelizumab Q&A with Dr. Tim Vollmer канала TheMSCenter
Видео Multiple Sclerosis Webinar: Ocrelizumab Q&A with Dr. Tim Vollmer канала TheMSCenter
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Ocrelizumab: What to Know About the First Agent Approved for Primary Progressive MS
Dietary Approaches to Treating Multiple Sclerosis-Related Fatigue with Terry Wahls, MD
Multiple Sclerosis Webinar: A Deep Dive into DMTs
What You Need to Know About Ocrevus
Recent Advances in the Treatment of Multiple Sclerosis: Are We There Yet?
Differences between Relapsing remitting MS and Progressive MS
Wat is vermoeidheid bij MS?
Latest MS Research Updates: A Review of the Most Promising MS Research Happening Now
Antientzündungstherapie für MS-Patienten - Erfahrungsberichte Teil 4
Ocrelizumab Use in Treating Multiple Sclerosis
MS: A Most Unusual Disease - Ben Thrower, M D - September 2015
Primer Progresif Multipl Skleroz’da Ocrelizumab Tedavisi
Monoclonal Antibodies | Health | Biology | FuseSchool
B Cells and Ocrelizumab
Ocrevus Infusion Experience
What is Progression in Multiple Sclerosis?
Multiple Sklerose: Gesundheitsmagazin "Kopfsache" vom 28.03.2019![Remyelination with Opicinumab (Anti-LINGO-1) for Multiple Sclerosis [Phase II Trial Results]](https://i.ytimg.com/vi/-t5eX8P_JEw/default.jpg)
Remyelination with Opicinumab (Anti-LINGO-1) for Multiple Sclerosis [Phase II Trial Results]
Highly Effective Disease-Modifying Therapies for Multiple Sclerosis
برنامج تم مرض التصلب المتعدد